Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL10383408 | 0.88 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| Sulfuric Acid SCHEMBL11299973 | 0.85 | ALDH1A1 (0.50) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| Tetrahydrofuran SCHEMBL11757674 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| Dioxane SCHEMBL4303266 | 0.84 | TTR (0.43) | TSHRSMN1; SMN2L3MBTL1CA12CA7 | |
| Tetrahydrofuran SCHEMBL11859013 | 0.84 | ALDH1A1 (0.57) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| SCHEMBL4025713 | 0.82 | ALDH1A1 (0.47) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| SCHEMBL28280266 | 0.82 | ALDH1A1 (0.47) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| Tetrahydrofuran SCHEMBL28286991 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| Tetrahydrofuran SCHEMBL27890142 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 | |
| Tetrahydrofuran SCHEMBL11475139 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRSMN1; SMN2L3MBTL1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060287535-A1 | Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide | WOCKHARDT LIMITED | 2006-12-21 | — | — | US | disclosed |
| EP-1682522-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | Wockhardt Limited (IN) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044808-A1 | A PROCESS FOR THE MANUFACTURE OF ZONISAMIDE | WOCKHARDT LIMITED (IN) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287535-A1 | Process for the manufacture of 1,2-benzisoxazole-3-methanesulphonamide | GABRE, CA3, GABRA1 | ALDH1A1 2084/4885TSHR 3020/4885SMN1; SMN2 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.